Press Release

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)

Share this article:
Facebook
Twitter
LinkedIn
Email
Print

Have questions or want to connect?

We’re here to help—reach out to learn more about Quetzal Therapeutics and our mission.
Contact Us